Global Angiotensin Converting Enzyme Inhibitors Market Growth (Status and Outlook) 2025-2031

According to this study, the global Angiotensin Converting Enzyme Inhibitors market size will reach US$ million by 2031.

Angiotensin converting enzyme inhibitors (ACE inhibitors) are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

LPI (LP Information)' newest research report, the “Angiotensin Converting Enzyme Inhibitors Industry Forecast” looks at past sales and reviews total world Angiotensin Converting Enzyme Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Angiotensin Converting Enzyme Inhibitors sales for 2025 through 2031. With Angiotensin Converting Enzyme Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiotensin Converting Enzyme Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Angiotensin Converting Enzyme Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Angiotensin Converting Enzyme Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Angiotensin Converting Enzyme Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Converting Enzyme Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Converting Enzyme Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Converting Enzyme Inhibitors market by product type, application, key players and key regions and countries.

Segmentation by Type:
Benazepril (Lotensin)
Captopril
Enalapril (Vasotec)
Fosinopril
Lisinopril (Prinivil, Zestril)
Moexipril
Perindopril
Quinapril (Accupril)
Ramipril (Altace)
Trandolapril

Segmentation by Application:
Coronary Artery Disease
Heart Failure
Diabetes
Chronic Kidney Diseases
Heart Attacks
Scleroderma
Migraines
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott

Please note: The report will take approximately 2 business days to prepare and deliver. Show more